Hemophilia: History and Discovery

The story of hemophilia is a rare case in which ordinary people recognized the true pattern of an inherited disease nearly two thousand years before science could explain it. Rabbinic authorities of the second century CE saw that some families lost boy after boy to uncontrollable bleeding, and that the danger passed silently through mothers to their sons. A Philadelphia physician, John Conrad Otto, set that observation down in print in 1803; a Zurich dissertation gave the condition its name around 1828; Queen Victoria carried it into the royal houses of Europe; and only in the twentieth century did researchers learn that “hemophilia” was in fact two diseases — a deficiency of clotting Factor VIII or of Factor IX — the second of which acquired the gentle, almost whimsical name “Christmas disease” in 1952. This page traces that long arc, naming names and dates carefully and flagging where the historical record is uncertain.

Ancient Awareness: The Talmud and the Maternal Line
John Conrad Otto and the “Bleeders” of 1803
Naming the Disease: Zurich, c. 1828
The “Royal Disease”: Queen Victoria and the Romanovs
Finding the Missing Factor: 1937 and Factor VIII
Two Diseases, Not One: Hemophilia A and B
Christmas Disease: A Patient, a Journal, and 1952
From Recognition to Treatment: The Modern Legacy
Research Papers and References
Connections

Ancient Awareness: The Talmud and the Maternal Line

Long before anyone could speak of genes or chromosomes, an inherited bleeding tendency had been noticed and recorded in the Jewish rabbinic tradition. The Babylonian Talmud preserves a discussion, attributed to authorities of roughly the second to third centuries CE, ruling that a male infant should be exempted from ritual circumcision (brit milah) if earlier sons in the same family had bled to death after the procedure. According to the teaching attributed to Rabbi Judah ha-Nasi (Rebbi, c. 135–217 CE), two such prior deaths were enough to establish the danger; Rabbi Shimon ben Gamliel is recorded as requiring three. These texts are named here as historical primary sources, not as modern medical citations.

What is genuinely remarkable is the inheritance logic embedded in the ruling. The exemption was framed in terms of the boy's brothers and his maternal cousins — the sons of his mother's sisters — and Maimonides, commenting centuries later, explicitly noted that it applied through the mother's line and not the father's. In modern terms this is a precise, if intuitive, description of X-linked recessive inheritance: a disorder carried by unaffected women and expressed in their sons. The rabbis did not know why the pattern held, but they had read the pattern correctly from careful observation of real families across generations.

This makes the Talmudic passage one of the earliest clear recognitions of a hereditary disease anywhere in the human record, and the earliest known recognition of hemophilia specifically. It is worth being precise about what it is and is not: it is an ancient, accurate observation of a sex-linked, maternally transmitted bleeding tendency — not a diagnosis of “hemophilia A” as such, since the distinction between hemophilia A and B would not exist for another eighteen centuries. The ancient awareness was of the pattern; the molecular identity came much later.

Back to Table of Contents

John Conrad Otto and the “Bleeders” of 1803

The first detailed clinical description of hemophilia in the modern medical literature came from Philadelphia. In 1803 the physician John Conrad Otto (1774–1844), a student of the famous Benjamin Rush, published a paper in the Medical Repository under the title “An Account of an Hæmorrhagic Disposition Existing in Certain Families.” In it he described what he called “bleeders”: individuals, almost all of them male, prone to alarming and sometimes fatal bleeding from minor injuries, and he traced the tendency back through several generations of affected American families.

Otto grasped the three cardinal features of the disorder with a clarity that still reads well today. He recognized that the condition was hereditary, that it affected males almost exclusively, and — the crucial insight — that it was transmitted through unaffected females who did not bleed themselves but passed the tendency to their sons. He famously followed one such lineage back to a woman who had settled near Plymouth, New Hampshire, around 1720, whose healthy daughters carried the trait onward to bleeding grandsons and great-grandsons. This is, in effect, the same maternal-line pattern the Talmud had recorded, now documented as a clinical case study.

Otto's 1803 paper is conventionally treated as the foundational modern description of hemophilia, and it is why many histories mark that year as a turning point. He did not coin the word “hemophilia” — that came a quarter-century later and elsewhere — and he did not, of course, know the biochemical cause. What he provided was an accurate, well-traced natural history of the disease as an inherited, male-affecting, female-transmitted bleeding disorder, establishing it as a recognized medical entity in the Western literature.

Back to Table of Contents

Naming the Disease: Zurich, c. 1828

The name by which we know the disease today arose in the German-speaking world around 1828, in the orbit of the University of Zurich. It appears in a doctoral dissertation usually dated to 1828, “Über die Hämophilie oder die erbliche Anlage zu tödtlichen Blutungen” (“On Hemophilia, or the Hereditary Predisposition to Fatal Bleeding”), associated with the student Friedrich Hopff and his supervisor, the prominent physician Johann Lukas Schönlein. The word is built from Greek roots and literally means something like “love of blood” — an etymological oddity, since the disease is defined by losing blood, not loving it.

The historical record is genuinely ambiguous about who deserves credit and about the exact form first used, and honest histories flag this. Some accounts credit Hopff with coining the term in his thesis; others attribute it to Schönlein. Several sources note that the term originally appeared in the more cumbersome form “hämorrhaphilie” (or “haemorrhaphilia”), which was later shortened to the smoother “hämophilie”/“haemophilia.” The spelling of the student's surname also varies between “Hopff” and “Hopf” across the literature. The safe, well-supported statement is that the term entered medicine around 1828 from the Hopff–Schönlein circle in Zurich; the finer points of attribution remain disputed.

Whoever fixed the word, its adoption mattered. A shared, memorable name turned a scattered set of family case reports into a single recognized condition that physicians across Europe could discuss, compare, and study. Within a few decades “hemophilia” was standard medical vocabulary, even though the actual defect in the blood would remain a mystery for another full century.

Back to Table of Contents

The “Royal Disease”: Queen Victoria and the Romanovs

Hemophilia entered public consciousness above all through the royal houses of nineteenth- and early-twentieth-century Europe, earning it the nickname “the royal disease.” Queen Victoria of the United Kingdom (1819–1901) was a carrier. Because there was no known hemophilia in her ancestry, geneticists generally conclude that the mutation arose spontaneously — either in Victoria herself or in the germ cells of one of her parents — making her a textbook example of a new (de novo) mutation in a famous individual. Her son Prince Leopold was affected and died young after a fall, and two of her daughters, Princess Alice and Princess Beatrice, were carriers who married into other dynasties.

Through those daughters the mutation spread into the royal families of Germany, Spain, and Russia. The most historically consequential case was in Russia: Victoria's granddaughter Alix (Empress Alexandra) carried the trait to her son Alexei Nikolaevich, the Tsarevich and heir to the Romanov throne (born 1904). Alexei's severe, life-threatening bleeding episodes drew the family into dependence on the faith healer Grigori Rasputin, whose apparent ability to calm the boy gave him extraordinary influence at court — a factor many historians count among the strains on the late Russian monarchy before its fall in 1917.

For more than a century the exact type of hemophilia in Victoria's descendants was unknown, because the last affected male relatives died before modern testing existed. The question was settled only in 2009, when a research team led by Evgeny Rogaev performed genetic analysis on skeletal remains identified as those of the murdered Romanovs, including Alexei. They located a specific mutation in the F9 gene, which encodes clotting Factor IX, establishing that the royal disease was hemophilia B. This is a clean example of a centuries-old historical question answered definitively by DNA evidence rather than by inference.

Back to Table of Contents

Finding the Missing Factor: 1937 and Factor VIII

For all that physicians could describe and name hemophilia, they could not say what was actually wrong with the blood until the twentieth century. The decisive step came in 1937, when the Harvard physicians Arthur J. Patek and F. H. Laskey Taylor reported that the abnormally slow clotting of hemophilic blood could be corrected by adding a substance extracted from normal plasma. They called this missing ingredient “antihemophilic globulin” (later “antihemophilic factor,” and in the standardized Roman-numeral nomenclature, Factor VIII).

This was a conceptual breakthrough: it reframed hemophilia from a vaguely understood family curse into a specific, measurable deficiency of a single plasma component — something that could, in principle, be replaced. It also pointed directly toward therapy. If the defect was a missing clotting factor, then supplying that factor — first through whole blood and plasma, later through purified concentrates — should treat or prevent bleeding, which is exactly the logic on which all modern factor-replacement therapy rests.

It is worth keeping the chronology honest here. The 1937 work identified a missing factor, but at the time hemophilia was still treated as one disease. The realization that the same clinical picture could be produced by a deficiency of a different factor — and therefore that there was more than one hemophilia — came in the years immediately following, and is the subject of the next section.

Back to Table of Contents

Two Diseases, Not One: Hemophilia A and B

By the mid-twentieth century, careful laboratory work began to reveal that “hemophilia” was not a single entity. A pivotal clue came from the Argentine physician Alfredo Pavlovsky in Buenos Aires (reported in 1947): he observed that when blood from one hemophilic patient was mixed with, or transfused into, certain other hemophilic patients, the clotting defect was corrected — something that should have been impossible if every patient lacked the very same factor. The implication, not fully appreciated at first, was that different patients were missing different components, so that one patient's plasma could supply what another's lacked.

That interpretation crystallized in 1952. Working in San Francisco, Robert Aggeler and colleagues described a patient deficient not in Factor VIII but in a distinct clotting protein they named “plasma thromboplastin component” (PTC) — the factor later standardized as Factor IX. A deficiency of Factor VIII became known as hemophilia A, and a deficiency of Factor IX as hemophilia B. The two are clinically very similar — the same kind of joint and soft-tissue bleeding, the same X-linked inheritance — but they are biochemically separate disorders requiring different replacement factors, which is why telling them apart mattered enormously for treatment.

This distinction is what retroactively made the 2009 Romanov DNA result meaningful: identifying Alexei's defect specifically in the Factor IX (F9) gene is what classified the royal disease as hemophilia B rather than the more common hemophilia A. The mid-century split of one disease into two is therefore not a mere technicality; it is the framework within which essentially all later genetics and therapy of hemophilia is organized.

Back to Table of Contents

Christmas Disease: A Patient, a Journal, and 1952

Hemophilia B carries one of the most charming eponyms in medicine: “Christmas disease.” The name does not refer to the holiday. It honors a patient. In 1952 a young Canadian boy named Stephen Christmas — who had been diagnosed with hemophilia in Toronto — was in London when a sample of his blood reached the Oxford Haemophilia Centre. There the team led by Rosemary Biggs and Robert Gwyn Macfarlane established that he was deficient not in Factor VIII but in the newly recognized other factor. The protein was dubbed the “Christmas factor” in his honor, and is now known as Factor IX.

The finding was published in the British Medical Journal in its December 1952 issue, in a paper by Biggs, Macfarlane, and co-authors titled “Christmas Disease: A Condition Previously Mistaken for Haemophilia.” The combination of the surname and the December publication date was so improbable that some readers reportedly suspected a seasonal joke. Biggs later explained that the team had chosen “Christmas disease” deliberately as a “legitimate, unassuming, and pleasantly provocative” way to distinguish the new condition from classic hemophilia — an eponym tied to the patient who revealed it.

Stephen Christmas himself did not remain merely a footnote. He grew up to become an advocate for people with bleeding disorders and for blood safety, and he died in 1993. His name endures both in the older clinical term “Christmas disease” and in “Christmas factor,” a small permanent reminder that a major piece of hematology was unlocked through the case of one identified child.

Back to Table of Contents

From Recognition to Treatment: The Modern Legacy

Once hemophilia was understood as a deficiency of a specific, replaceable clotting factor, the second half of the twentieth century turned toward putting that factor back. Early treatment relied on whole blood and fresh plasma; a major advance came in 1964–1965 when Judith Graham Pool described cryoprecipitate — the Factor-VIII-rich material that precipitates when frozen plasma is slowly thawed — making concentrated replacement practical. Freeze-dried clotting-factor concentrates followed, allowing patients to treat bleeds promptly and, eventually, to prevent them with regular prophylaxis.

This progress carried a tragic chapter that any honest history must acknowledge. Because plasma-derived concentrates were pooled from many thousands of donors, in the late 1970s and 1980s a large share of people with hemophilia were infected with hepatitis viruses and with HIV through contaminated products, before effective donor screening and viral inactivation existed. The resulting loss of life within the bleeding-disorders community was devastating, and it drove lasting reforms in blood safety and the development of virally inactivated and recombinant (non-plasma) factor products from the 1980s and 1990s onward.

The modern era continues that trajectory toward safer and more durable treatment: recombinant Factor VIII and Factor IX, longer-acting engineered factors, non-factor therapies, and gene-therapy approaches aimed at enabling the body to make its own clotting factor. The throughline from the Talmud to the genome is striking — an inheritance pattern read correctly in antiquity, a disease described in 1803 and named around 1828, split into two disorders and given the “Christmas” eponym in 1952, traced to Factor IX in the Romanovs in 2009, and now addressed at the level of the gene itself. For the clinical picture, modern diagnosis, and current management, see the main Hemophilia article.

Back to Table of Contents

Research Papers and References

The references below combine peer-reviewed historical reviews with curated PubMed topic-search links into the primary literature on the discovery and naming of hemophilia. Historical primary texts (the Babylonian Talmud; Otto's 1803 Medical Repository account; the c. 1828 Hopff–Schönlein Zurich dissertation; and the 1952 BMJ “Christmas disease” paper) are named in the article as historical sources. Links open at PubMed or the publisher in a new tab; where a stable DOI/PMID was not confidently verified, a PubMed topic search is given instead.

Rosner F. Hemophilia in the Talmud and rabbinic writings. Annals of Internal Medicine. 1969;70(4):833–837. — doi:10.7326/0003-4819-70-4-833
Otto JC. An account of an hæmorrhagic disposition existing in certain families (1803) — historical reprint and commentary — PubMed: Otto 1803 haemorrhagic disposition
Schramm W. The history of haemophilia — a short review. Thrombosis Research. 2014;134 Suppl 1:S4–S9. — doi:10.1016/j.thromres.2013.10.020
Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet Journal of Rare Diseases. 2012;7:24. — doi:10.1186/1750-1172-7-24
Rogaev EI, Grigorenko AP, Faskhutdinova G, Kittler ELW, Moliaka YK. Genotype analysis identifies the cause of the “royal disease.” Science. 2009;326(5954):817. — doi:10.1126/science.1180660
Biggs R, Douglas AS, Macfarlane RG, et al. Christmas disease: a condition previously mistaken for haemophilia. British Medical Journal. 1952;2(4799):1378–1382. — doi:10.1136/bmj.2.4799.1378
Aggeler PM, et al. Plasma thromboplastin component (PTC) deficiency; a new disease resembling hemophilia. Proceedings of the Society for Experimental Biology and Medicine. 1952;79(4):692–694. — PubMed (PMID 14920537)
Patek AJ, Taylor FHL — antihemophilic globulin and the plasma defect in hemophilia (1937) — PubMed: Patek & Taylor antihemophilic globulin
Haemophilia A and B nomenclature — Factor VIII vs Factor IX history — PubMed: hemophilia A and B classification history
Hemophilia in European royalty — Queen Victoria and the Romanovs — PubMed: hemophilia royal disease Victoria Romanov
Stephen Christmas, the eponym, and the Oxford Haemophilia Centre — PubMed: Christmas disease history factor IX
Pool JG — cryoprecipitate and the development of factor concentrates — PubMed: cryoprecipitate Pool factor VIII history
HIV and hepatitis contamination of clotting-factor concentrates — the bleeding-disorders community — PubMed: hemophilia HIV hepatitis factor concentrate history

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents